Inserm U1086 ANTICIPE, François Baclesse Comprehensive Cancer Center, in collaboration with Université de Caen Normandie
2 weeks ago
PhD in Cancer Biology and Ovarian Cancer Immunotherapy at Inserm U1086 ANTICIPE Inserm U1086 ANTICIPE, François Baclesse Comprehensive Cancer Center, in collaboration with Université de Caen Normandie in France
Degree Level
PhD
Field of study
Cell Biology
Funding
36-month PhD position starting January or February 2027. The post is presented as a PhD opening; no stipend amount or tuition details are stated.
Deadline
Oct 31, 2026
Country
France
University
Inserm U1086 ANTICIPE, François Baclesse Comprehensive Cancer Center, in collaboration with Université de Caen Normandie
How do I apply for this?
Sign in for free to reveal details, requirements, and source links.
Apply for this position
Keywords
Suggested positions
About this position
PhD opening in Cancer Biology at Inserm U1086 ANTICIPE, François Baclesse Comprehensive Cancer Center, in collaboration with Université de Caen Normandie, France.
The project is titled “Targeting UBE2N and antitumor immunity for improved ovarian cancer treatment” and sits within the BioTICLA precision medicine in ovarian cancer axis, with access to the ORGAPRED tumor organoid core facility.
Research tasks include characterizing UBE2N-targeting compounds and their effects in ovarian cancer models; studying the interplay between UBE2N-dependent processes and antitumor immune signaling; testing treatment combinations in cell lines and patient-derived tumor organoids (PDTO) using viability, proliferation, and cytotoxicity assays; and possibly extending to preclinical in vivo studies. The student will also prepare manuscripts and present at conferences.
Desired background includes knowledge of DNA repair and anticancer pharmacology and/or therapeutic combination studies, mammalian cell culture experience, and the ability to design and optimize protocols with increasing autonomy. Good scientific English is required. Experience with PDTO, functional assays, in vivo mouse models, or cancer immunology/immuno-oncology is an asset.
Eligibility: Master's degree or equivalent recognized in France/the EU in cancer biology, cell and molecular biology, pharmacology, immunology, or a related field.
Duration is 36 months, with a start date in January or February 2027. Deadline: 31 October 2026.
How to apply: email both supervisors with a CV, Master's transcripts, one reference letter or referee contact details, and a brief motivation statement linking your background to the U-STING project.
Funding details
36-month PhD position starting January or February 2027. The post is presented as a PhD opening; no stipend amount or tuition details are stated.
What's required
Master's degree or equivalent recognized in France/the EU in cancer biology, cell and molecular biology, pharmacology, immunology, or a related field. Applicants should know DNA repair and anticancer pharmacology and/or therapeutic combination studies, have experience in mammalian cell culture, be able to design and optimize protocols with increasing autonomy, and have good scientific English. Experience with patient-derived tumor organoids, functional assays, in vivo mouse models, or cancer immunology/immuno-oncology is an asset or strong advantage.
How to apply
Send your application to both supervisors by email. Include a CV, Master's transcripts, one reference letter or contact details of one academic or research referee, and a brief motivation letter explaining how your background relates to the U-STING project.
More information can be found here
Ask ApplyKite AI
How do I apply for this?
Sign in for free to reveal details, requirements, and source links.